1 Market Overview

1.1 Product Overview and Scope of Macular Degeneration Drug Pipeline

1.2 Classification of Macular Degeneration Drug Pipeline by Type

1.2.1 Overview: Global Macular Degeneration Drug Pipeline Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Macular Degeneration Drug Pipeline Revenue Market Share by Type in 2020

1.2.3 Gene therapy

1.2.4 Small molecules

1.2.5 Stem cell therapy

1.2.6 Gene therapies

1.3 Global Macular Degeneration Drug Pipeline Market by Application

1.3.1 Overview: Global Macular Degeneration Drug Pipeline Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Hospital

1.3.3 Research Institute

1.3.4 Commercial

1.3.5 Other

1.4 Global Macular Degeneration Drug Pipeline Market Size & Forecast

1.5 Global Macular Degeneration Drug Pipeline Market Size and Forecast by Region

1.5.1 Global Macular Degeneration Drug Pipeline Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Macular Degeneration Drug Pipeline Market Size by Region, (2016-2021)

1.5.3 North America Macular Degeneration Drug Pipeline Market Size and Prospect (2016-2026)

1.5.4 Europe Macular Degeneration Drug Pipeline Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific Macular Degeneration Drug Pipeline Market Size and Prospect (2016-2026)

1.5.6 South America Macular Degeneration Drug Pipeline Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa Macular Degeneration Drug Pipeline Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Macular Degeneration Drug Pipeline Market Drivers

1.6.2 Macular Degeneration Drug Pipeline Market Restraints

1.6.3 Macular Degeneration Drug Pipeline Trends Analysis

2 Company Profiles

2.1 Amgen

2.1.1 Amgen Details

2.1.2 Amgen Major Business

2.1.3 Amgen Macular Degeneration Drug Pipeline Product and Solutions

2.1.4 Amgen Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 Amgen Recent Developments and Future Plans

2.2 Roche

2.2.1 Roche Details

2.2.2 Roche Major Business

2.2.3 Roche Macular Degeneration Drug Pipeline Product and Solutions

2.2.4 Roche Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 Roche Recent Developments and Future Plans

2.3 Adverum Biotechnologies

2.3.1 Adverum Biotechnologies Details

2.3.2 Adverum Biotechnologies Major Business

2.3.3 Adverum Biotechnologies Macular Degeneration Drug Pipeline Product and Solutions

2.3.4 Adverum Biotechnologies Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 Adverum Biotechnologies Recent Developments and Future Plans

2.4 AsclepiX Therapeutics

2.4.1 AsclepiX Therapeutics Details

2.4.2 AsclepiX Therapeutics Major Business

2.4.3 AsclepiX Therapeutics Macular Degeneration Drug Pipeline Product and Solutions

2.4.4 AsclepiX Therapeutics Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 AsclepiX Therapeutics Recent Developments and Future Plans

2.5 Bioeq AG

2.5.1 Bioeq AG Details

2.5.2 Bioeq AG Major Business

2.5.3 Bioeq AG Macular Degeneration Drug Pipeline Product and Solutions

2.5.4 Bioeq AG Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Bioeq AG Recent Developments and Future Plans

2.6 Sinocelltech

2.6.1 Sinocelltech Details

2.6.2 Sinocelltech Major Business

2.6.3 Sinocelltech Macular Degeneration Drug Pipeline Product and Solutions

2.6.4 Sinocelltech Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 Sinocelltech Recent Developments and Future Plans

2.7 RemeGen

2.7.1 RemeGen Details

2.7.2 RemeGen Major Business

2.7.3 RemeGen Macular Degeneration Drug Pipeline Product and Solutions

2.7.4 RemeGen Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 RemeGen Recent Developments and Future Plans

2.8 Grifols, S.A.

2.8.1 Grifols, S.A. Details

2.8.2 Grifols, S.A. Major Business

2.8.3 Grifols, S.A. Macular Degeneration Drug Pipeline Product and Solutions

2.8.4 Grifols, S.A. Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.8.5 Grifols, S.A. Recent Developments and Future Plans

2.9 Kyowa Kirin

2.9.1 Kyowa Kirin Details

2.9.2 Kyowa Kirin Major Business

2.9.3 Kyowa Kirin Macular Degeneration Drug Pipeline Product and Solutions

2.9.4 Kyowa Kirin Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.9.5 Kyowa Kirin Recent Developments and Future Plans

2.10 EyePoint Pharmaceutical

2.10.1 EyePoint Pharmaceutical Details

2.10.2 EyePoint Pharmaceutical Major Business

2.10.3 EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Product and Solutions

2.10.4 EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.10.5 EyePoint Pharmaceutical Recent Developments and Future Plans

2.11 IVERIC Bio

2.11.1 IVERIC Bio Details

2.11.2 IVERIC Bio Major Business

2.11.3 IVERIC Bio Macular Degeneration Drug Pipeline Product and Solutions

2.11.4 IVERIC Bio Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.11.5 IVERIC Bio Recent Developments and Future Plans

2.12 Kodiak Sciences

2.12.1 Kodiak Sciences Details

2.12.2 Kodiak Sciences Major Business

2.12.3 Kodiak Sciences Macular Degeneration Drug Pipeline Product and Solutions

2.12.4 Kodiak Sciences Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.12.5 Kodiak Sciences Recent Developments and Future Plans

2.13 Ribomic

2.13.1 Ribomic Details

2.13.2 Ribomic Major Business

2.13.3 Ribomic Macular Degeneration Drug Pipeline Product and Solutions

2.13.4 Ribomic Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.13.5 Ribomic Recent Developments and Future Plans

2.14 Lineage Cell Therapeutics

2.14.1 Lineage Cell Therapeutics Details

2.14.2 Lineage Cell Therapeutics Major Business

2.14.3 Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Product and Solutions

2.14.4 Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.14.5 Lineage Cell Therapeutics Recent Developments and Future Plans

2.15 Graybug Vision

2.15.1 Graybug Vision Details

2.15.2 Graybug Vision Major Business

2.15.3 Graybug Vision Macular Degeneration Drug Pipeline Product and Solutions

2.15.4 Graybug Vision Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.15.5 Graybug Vision Recent Developments and Future Plans

2.16 CHABiotech

2.16.1 CHABiotech Details

2.16.2 CHABiotech Major Business

2.16.3 CHABiotech Macular Degeneration Drug Pipeline Product and Solutions

2.16.4 CHABiotech Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.16.5 CHABiotech Recent Developments and Future Plans

2.17 Shanghai Henlius Biotech

2.17.1 Shanghai Henlius Biotech Details

2.17.2 Shanghai Henlius Biotech Major Business

2.17.3 Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Product and Solutions

2.17.4 Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.17.5 Shanghai Henlius Biotech Recent Developments and Future Plans

2.18 Bio-Thera Solutions

2.18.1 Bio-Thera Solutions Details

2.18.2 Bio-Thera Solutions Major Business

2.18.3 Bio-Thera Solutions Macular Degeneration Drug Pipeline Product and Solutions

2.18.4 Bio-Thera Solutions Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.18.5 Bio-Thera Solutions Recent Developments and Future Plans

2.19 Alteogen

2.19.1 Alteogen Details

2.19.2 Alteogen Major Business

2.19.3 Alteogen Macular Degeneration Drug Pipeline Product and Solutions

2.19.4 Alteogen Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.19.5 Alteogen Recent Developments and Future Plans

2.20 Outlook Therapeutics

2.20.1 Outlook Therapeutics Details

2.20.2 Outlook Therapeutics Major Business

2.20.3 Outlook Therapeutics Macular Degeneration Drug Pipeline Product and Solutions

2.20.4 Outlook Therapeutics Macular Degeneration Drug Pipeline Revenue, Gross Margin and Market Share (2019-2021)

2.20.5 Outlook Therapeutics Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Macular Degeneration Drug Pipeline Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 3 Macular Degeneration Drug Pipeline Players Market Share

3.2.2 Top 10 Macular Degeneration Drug Pipeline Players Market Share

3.2.3 Market Competition Trend

3.3 Macular Degeneration Drug Pipeline Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Macular Degeneration Drug Pipeline Revenue and Market Share by Type (2016-2021)

4.2 Global Macular Degeneration Drug Pipeline Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Macular Degeneration Drug Pipeline Revenue Market Share by Application (2016-2021)

5.2 Macular Degeneration Drug Pipeline Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America Macular Degeneration Drug Pipeline Revenue by Type (2016-2026)

6.2 North America Macular Degeneration Drug Pipeline Revenue by Application (2016-2026)

6.3 North America Macular Degeneration Drug Pipeline Market Size by Country

6.3.1 North America Macular Degeneration Drug Pipeline Revenue by Country (2016-2026)

6.3.2 United States Macular Degeneration Drug Pipeline Market Size and Forecast (2016-2026)

6.3.3 Canada Macular Degeneration Drug Pipeline Market Size and Forecast (2016-2026)

6.3.4 Mexico Macular Degeneration Drug Pipeline Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe Macular Degeneration Drug Pipeline Revenue by Type (2016-2026)

7.2 Europe Macular Degeneration Drug Pipeline Revenue by Application (2016-2026)

7.3 Europe Macular Degeneration Drug Pipeline Market Size by Country

7.3.1 Europe Macular Degeneration Drug Pipeline Revenue by Country (2016-2026)

7.3.2 Germany Macular Degeneration Drug Pipeline Market Size and Forecast (2016-2026)

7.3.3 France Macular Degeneration Drug Pipeline Market Size and Forecast (2016-2026)

7.3.4 United Kingdom Macular Degeneration Drug Pipeline Market Size and Forecast (2016-2026)

7.3.5 Russia Macular Degeneration Drug Pipeline Market Size and Forecast (2016-2026)

7.3.6 Italy Macular Degeneration Drug Pipeline Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Macular Degeneration Drug Pipeline Revenue by Type (2016-2026)

8.2 Asia-Pacific Macular Degeneration Drug Pipeline Revenue by Application (2016-2026)

8.3 Asia-Pacific Macular Degeneration Drug Pipeline Market Size by Region

8.3.1 Asia-Pacific Macular Degeneration Drug Pipeline Revenue by Region (2016-2026)

8.3.2 China Macular Degeneration Drug Pipeline Market Size and Forecast (2016-2026)

8.3.3 Japan Macular Degeneration Drug Pipeline Market Size and Forecast (2016-2026)

8.3.4 South Korea Macular Degeneration Drug Pipeline Market Size and Forecast (2016-2026)

8.3.5 India Macular Degeneration Drug Pipeline Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia Macular Degeneration Drug Pipeline Market Size and Forecast (2016-2026)

8.3.7 Australia Macular Degeneration Drug Pipeline Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America Macular Degeneration Drug Pipeline Revenue by Type (2016-2026)

9.2 South America Macular Degeneration Drug Pipeline Revenue by Application (2016-2026)

9.3 South America Macular Degeneration Drug Pipeline Market Size by Country

9.3.1 South America Macular Degeneration Drug Pipeline Revenue by Country (2016-2026)

9.3.2 Brazil Macular Degeneration Drug Pipeline Market Size and Forecast (2016-2026)

9.3.3 Argentina Macular Degeneration Drug Pipeline Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Macular Degeneration Drug Pipeline Revenue by Type (2016-2026)

10.2 Middle East & Africa Macular Degeneration Drug Pipeline Revenue by Application (2016-2026)

10.3 Middle East & Africa Macular Degeneration Drug Pipeline Market Size by Country

10.3.1 Middle East & Africa Macular Degeneration Drug Pipeline Revenue by Country (2016-2026)

10.3.2 Turkey Macular Degeneration Drug Pipeline Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia Macular Degeneration Drug Pipeline Market Size and Forecast (2016-2026)

10.3.4 UAE Macular Degeneration Drug Pipeline Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Macular Degeneration Drug Pipeline Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Macular Degeneration Drug Pipeline Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Macular Degeneration Drug Pipeline Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Macular Degeneration Drug Pipeline Revenue (USD Million) by Region (2016-2021)

Table 5. Global Macular Degeneration Drug Pipeline Revenue Market Share by Region (2021-2026)

Table 6. Amgen Corporate Information, Head Office, and Major Competitors

Table 7. Amgen Major Business

Table 8. Amgen Macular Degeneration Drug Pipeline Product and Solutions

Table 9. Amgen Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. Roche Corporate Information, Head Office, and Major Competitors

Table 11. Roche Major Business

Table 12. Roche Macular Degeneration Drug Pipeline Product and Solutions

Table 13. Roche Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. Adverum Biotechnologies Corporate Information, Head Office, and Major Competitors

Table 15. Adverum Biotechnologies Major Business

Table 16. Adverum Biotechnologies Macular Degeneration Drug Pipeline Product and Solutions

Table 17. Adverum Biotechnologies Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. AsclepiX Therapeutics Corporate Information, Head Office, and Major Competitors

Table 19. AsclepiX Therapeutics Major Business

Table 20. AsclepiX Therapeutics Macular Degeneration Drug Pipeline Product and Solutions

Table 21. AsclepiX Therapeutics Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Bioeq AG Corporate Information, Head Office, and Major Competitors

Table 23. Bioeq AG Major Business

Table 24. Bioeq AG Macular Degeneration Drug Pipeline Product and Solutions

Table 25. Bioeq AG Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. Sinocelltech Corporate Information, Head Office, and Major Competitors

Table 27. Sinocelltech Major Business

Table 28. Sinocelltech Macular Degeneration Drug Pipeline Product and Solutions

Table 29. Sinocelltech Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. RemeGen Corporate Information, Head Office, and Major Competitors

Table 31. RemeGen Major Business

Table 32. RemeGen Macular Degeneration Drug Pipeline Product and Solutions

Table 33. RemeGen Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. Grifols, S.A. Corporate Information, Head Office, and Major Competitors

Table 35. Grifols, S.A. Major Business

Table 36. Grifols, S.A. Macular Degeneration Drug Pipeline Product and Solutions

Table 37. Grifols, S.A. Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 38. Kyowa Kirin Corporate Information, Head Office, and Major Competitors

Table 39. Kyowa Kirin Major Business

Table 40. Kyowa Kirin Macular Degeneration Drug Pipeline Product and Solutions

Table 41. Kyowa Kirin Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 42. EyePoint Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 43. EyePoint Pharmaceutical Major Business

Table 44. EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Product and Solutions

Table 45. EyePoint Pharmaceutical Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 46. IVERIC Bio Corporate Information, Head Office, and Major Competitors

Table 47. IVERIC Bio Major Business

Table 48. IVERIC Bio Macular Degeneration Drug Pipeline Product and Solutions

Table 49. IVERIC Bio Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 50. Kodiak Sciences Corporate Information, Head Office, and Major Competitors

Table 51. Kodiak Sciences Major Business

Table 52. Kodiak Sciences Macular Degeneration Drug Pipeline Product and Solutions

Table 53. Kodiak Sciences Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 54. Ribomic Corporate Information, Head Office, and Major Competitors

Table 55. Ribomic Major Business

Table 56. Ribomic Macular Degeneration Drug Pipeline Product and Solutions

Table 57. Ribomic Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 58. Lineage Cell Therapeutics Corporate Information, Head Office, and Major Competitors

Table 59. Lineage Cell Therapeutics Major Business

Table 60. Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Product and Solutions

Table 61. Lineage Cell Therapeutics Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 62. Graybug Vision Corporate Information, Head Office, and Major Competitors

Table 63. Graybug Vision Major Business

Table 64. Graybug Vision Macular Degeneration Drug Pipeline Product and Solutions

Table 65. Graybug Vision Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 66. CHABiotech Corporate Information, Head Office, and Major Competitors

Table 67. CHABiotech Major Business

Table 68. CHABiotech Macular Degeneration Drug Pipeline Product and Solutions

Table 69. CHABiotech Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 70. Shanghai Henlius Biotech Corporate Information, Head Office, and Major Competitors

Table 71. Shanghai Henlius Biotech Major Business

Table 72. Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Product and Solutions

Table 73. Shanghai Henlius Biotech Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 74. Bio-Thera Solutions Corporate Information, Head Office, and Major Competitors

Table 75. Bio-Thera Solutions Major Business

Table 76. Bio-Thera Solutions Macular Degeneration Drug Pipeline Product and Solutions

Table 77. Bio-Thera Solutions Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 78. Alteogen Corporate Information, Head Office, and Major Competitors

Table 79. Alteogen Major Business

Table 80. Alteogen Macular Degeneration Drug Pipeline Product and Solutions

Table 81. Alteogen Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 82. Outlook Therapeutics Corporate Information, Head Office, and Major Competitors

Table 83. Outlook Therapeutics Major Business

Table 84. Outlook Therapeutics Macular Degeneration Drug Pipeline Product and Solutions

Table 85. Outlook Therapeutics Macular Degeneration Drug Pipeline Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 86. Global Macular Degeneration Drug Pipeline Revenue (USD Million) by Players (2019-2021)

Table 87. Global Macular Degeneration Drug Pipeline Revenue Share by Players (2019-2021)

Table 88. Breakdown of Macular Degeneration Drug Pipeline by Company Type (Tier 1, Tier 2 and Tier 3)

Table 89. Macular Degeneration Drug Pipeline Players Head Office, Products and Services Provided

Table 90. Macular Degeneration Drug Pipeline Mergers & Acquisitions in the Past Five Years

Table 91. Macular Degeneration Drug Pipeline New Entrants and Expansion Plans

Table 92. Global Macular Degeneration Drug Pipeline Revenue (USD Million) by Type (2016-2021)

Table 93. Global Macular Degeneration Drug Pipeline Revenue Share by Type (2016-2021)

Table 94. Global Macular Degeneration Drug Pipeline Revenue Forecast by Type (2021-2026)

Table 95. Global Macular Degeneration Drug Pipeline Revenue by Application (2016-2021)

Table 96. Global Macular Degeneration Drug Pipeline Revenue Forecast by Application (2021-2026)

Table 97. North America Macular Degeneration Drug Pipeline Revenue by Type (2016-2021) & (USD Million)

Table 98. North America Macular Degeneration Drug Pipeline Revenue by Type (2021-2026) & (USD Million)

Table 99. North America Macular Degeneration Drug Pipeline Revenue by Application (2016-2021) & (USD Million)

Table 100. North America Macular Degeneration Drug Pipeline Revenue by Application (2021-2026) & (USD Million)

Table 101. North America Macular Degeneration Drug Pipeline Revenue by Country (2016-2021) & (USD Million)

Table 102. North America Macular Degeneration Drug Pipeline Revenue by Country (2021-2026) & (USD Million)

Table 103. Europe Macular Degeneration Drug Pipeline Revenue by Type (2016-2021) & (USD Million)

Table 104. Europe Macular Degeneration Drug Pipeline Revenue by Type (2021-2026) & (USD Million)

Table 105. Europe Macular Degeneration Drug Pipeline Revenue by Application (2016-2021) & (USD Million)

Table 106. Europe Macular Degeneration Drug Pipeline Revenue by Application (2021-2026) & (USD Million)

Table 107. Europe Macular Degeneration Drug Pipeline Revenue by Country (2016-2021) & (USD Million)

Table 108. Europe Macular Degeneration Drug Pipeline Revenue by Country (2021-2026) & (USD Million)

Table 109. Asia-Pacific Macular Degeneration Drug Pipeline Revenue by Type (2016-2021) & (USD Million)

Table 110. Asia-Pacific Macular Degeneration Drug Pipeline Revenue by Type (2021-2026) & (USD Million)

Table 111. Asia-Pacific Macular Degeneration Drug Pipeline Revenue by Application (2016-2021) & (USD Million)

Table 112. Asia-Pacific Macular Degeneration Drug Pipeline Revenue by Application (2021-2026) & (USD Million)

Table 113. Asia-Pacific Macular Degeneration Drug Pipeline Revenue by Region (2016-2021) & (USD Million)

Table 114. Asia-Pacific Macular Degeneration Drug Pipeline Revenue by Region (2021-2026) & (USD Million)

Table 115. South America Macular Degeneration Drug Pipeline Revenue by Type (2016-2021) & (USD Million)

Table 116. South America Macular Degeneration Drug Pipeline Revenue by Type (2021-2026) & (USD Million)

Table 117. South America Macular Degeneration Drug Pipeline Revenue by Application (2016-2021) & (USD Million)

Table 118. South America Macular Degeneration Drug Pipeline Revenue by Application (2021-2026) & (USD Million)

Table 119. South America Macular Degeneration Drug Pipeline Revenue by Country (2016-2021) & (USD Million)

Table 120. South America Macular Degeneration Drug Pipeline Revenue by Country (2021-2026) & (USD Million)

Table 121. Middle East & Africa Macular Degeneration Drug Pipeline Revenue by Type (2016-2021) & (USD Million)

Table 122. Middle East & Africa Macular Degeneration Drug Pipeline Revenue by Type (2021-2026) & (USD Million)

Table 123. Middle East & Africa Macular Degeneration Drug Pipeline Revenue by Application (2016-2021) & (USD Million)

Table 124. Middle East & Africa Macular Degeneration Drug Pipeline Revenue by Application (2021-2026) & (USD Million)

Table 125. Middle East & Africa Macular Degeneration Drug Pipeline Revenue by Country (2016-2021) & (USD Million)

Table 126. Middle East & Africa Macular Degeneration Drug Pipeline Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. Macular Degeneration Drug Pipeline Picture

Figure 2. Global Macular Degeneration Drug Pipeline Revenue Market Share by Type in 2020

Figure 3. Gene therapy

Figure 4. Small molecules

Figure 5. Stem cell therapy

Figure 6. Gene therapies

Figure 7. Macular Degeneration Drug Pipeline Revenue Market Share by Application in 2020

Figure 8. Hospital Picture

Figure 9. Research Institute Picture

Figure 10. Commercial Picture

Figure 11. Other Picture

Figure 12. Global Macular Degeneration Drug Pipeline Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 13. Global Macular Degeneration Drug Pipeline Revenue and Forecast (2016-2026) & (USD Million)

Figure 14. Global Macular Degeneration Drug Pipeline Revenue Market Share by Region (2016-2026)

Figure 15. Global Macular Degeneration Drug Pipeline Revenue Market Share by Region in 2020

Figure 16. North America Macular Degeneration Drug Pipeline Revenue (USD Million) and Growth Rate (2016-2026)

Figure 17. Europe Macular Degeneration Drug Pipeline Revenue (USD Million) and Growth Rate (2016-2026)

Figure 18. Asia-Pacific Macular Degeneration Drug Pipeline Revenue (USD Million) and Growth Rate (2016-2026)

Figure 19. South America Macular Degeneration Drug Pipeline Revenue (USD Million) and Growth Rate (2016-2026)

Figure 20. Middle East and Africa Macular Degeneration Drug Pipeline Revenue (USD Million) and Growth Rate (2016-2026)

Figure 21. Macular Degeneration Drug Pipeline Market Drivers

Figure 22. Macular Degeneration Drug Pipeline Market Restraints

Figure 23. Macular Degeneration Drug Pipeline Market Trends

Figure 24. Amgen Recent Developments and Future Plans

Figure 25. Roche Recent Developments and Future Plans

Figure 26. Adverum Biotechnologies Recent Developments and Future Plans

Figure 27. AsclepiX Therapeutics Recent Developments and Future Plans

Figure 28. Bioeq AG Recent Developments and Future Plans

Figure 29. Sinocelltech Recent Developments and Future Plans

Figure 30. RemeGen Recent Developments and Future Plans

Figure 31. Grifols, S.A. Recent Developments and Future Plans

Figure 32. Kyowa Kirin Recent Developments and Future Plans

Figure 33. EyePoint Pharmaceutical Recent Developments and Future Plans

Figure 34. IVERIC Bio Recent Developments and Future Plans

Figure 35. Kodiak Sciences Recent Developments and Future Plans

Figure 36. Ribomic Recent Developments and Future Plans

Figure 37. Lineage Cell Therapeutics Recent Developments and Future Plans

Figure 38. Graybug Vision Recent Developments and Future Plans

Figure 39. CHABiotech Recent Developments and Future Plans

Figure 40. Shanghai Henlius Biotech Recent Developments and Future Plans

Figure 41. Bio-Thera Solutions Recent Developments and Future Plans

Figure 42. Alteogen Recent Developments and Future Plans

Figure 43. Outlook Therapeutics Recent Developments and Future Plans

Figure 44. Global Macular Degeneration Drug Pipeline Revenue Share by Players in 2020

Figure 45. Macular Degeneration Drug Pipeline Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 46. Global Top 3 Players Macular Degeneration Drug Pipeline Revenue Market Share in 2020

Figure 47. Global Top 10 Players Macular Degeneration Drug Pipeline Revenue Market Share in 2020

Figure 48. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 49. Global Macular Degeneration Drug Pipeline Revenue Share by Type in 2020

Figure 50. Global Macular Degeneration Drug Pipeline Market Share Forecast by Type (2021-2026)

Figure 51. Global Macular Degeneration Drug Pipeline Revenue Share by Application in 2020

Figure 52. Global Macular Degeneration Drug Pipeline Market Share Forecast by Application (2021-2026)

Figure 53. North America Macular Degeneration Drug Pipeline Sales Market Share by Type (2016-2026)

Figure 54. North America Macular Degeneration Drug Pipeline Sales Market Share by Application (2016-2026)

Figure 55. North America Macular Degeneration Drug Pipeline Revenue Market Share by Country (2016-2026)

Figure 56. United States Macular Degeneration Drug Pipeline Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 57. Canada Macular Degeneration Drug Pipeline Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 58. Mexico Macular Degeneration Drug Pipeline Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 59. Europe Macular Degeneration Drug Pipeline Sales Market Share by Type (2016-2026)

Figure 60. Europe Macular Degeneration Drug Pipeline Sales Market Share by Application (2016-2026)

Figure 61. Europe Macular Degeneration Drug Pipeline Revenue Market Share by Country (2016-2026)

Figure 62. Germany Macular Degeneration Drug Pipeline Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 63. France Macular Degeneration Drug Pipeline Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 64. United Kingdom Macular Degeneration Drug Pipeline Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 65. Russia Macular Degeneration Drug Pipeline Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 66. Italy Macular Degeneration Drug Pipeline Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 67. Asia-Pacific Macular Degeneration Drug Pipeline Sales Market Share by Type (2016-2026)

Figure 68. Asia-Pacific Macular Degeneration Drug Pipeline Sales Market Share by Application (2016-2026)

Figure 69. Asia-Pacific Macular Degeneration Drug Pipeline Revenue Market Share by Region (2016-2026)

Figure 70. China Macular Degeneration Drug Pipeline Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 71. Japan Macular Degeneration Drug Pipeline Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 72. South Korea Macular Degeneration Drug Pipeline Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 73. India Macular Degeneration Drug Pipeline Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 74. Southeast Asia Macular Degeneration Drug Pipeline Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 75. Australia Macular Degeneration Drug Pipeline Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 76. South America Macular Degeneration Drug Pipeline Sales Market Share by Type (2016-2026)

Figure 77. South America Macular Degeneration Drug Pipeline Sales Market Share by Application (2016-2026)

Figure 78. South America Macular Degeneration Drug Pipeline Revenue Market Share by Country (2016-2026)

Figure 79. Brazil Macular Degeneration Drug Pipeline Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 80. Argentina Macular Degeneration Drug Pipeline Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 81. Middle East and Africa Macular Degeneration Drug Pipeline Sales Market Share by Type (2016-2026)

Figure 82. Middle East and Africa Macular Degeneration Drug Pipeline Sales Market Share by Application (2016-2026)

Figure 83. Middle East and Africa Macular Degeneration Drug Pipeline Revenue Market Share by Country (2016-2026)

Figure 84. Turkey Macular Degeneration Drug Pipeline Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 85. Saudi Arabia Macular Degeneration Drug Pipeline Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 86. UAE Macular Degeneration Drug Pipeline Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 87. Methodology

Figure 88. Research Process and Data Source